Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome: A Scoping Review
DOI:
https://doi.org/10.53843/bms.v10i14.742Keywords:
Transplante de Microbiota Fecal; Síndrome do Intestino Irritável; Microbioma GastrointestinalAbstract
Introduction: Fecal microbiota transplantation (FMT) involves the insertion of donor feces into the patient's gastrointestinal tract to modify their intestinal microbiota and achieve therapeutic benefits. Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by symptoms such as abdominal pain or discomfort, constipation, and diarrhea. Currently, the use of FMT in the treatment of IBS and its symptoms is highlighted. However, the efficiency of FMT in IBS is not fully clarified in the literature. Therefore, a scoping review was conducted to systematically analyze the literature on the subject and investigate the efficacy of the method. Methodology: The PRISMA-scR protocol, an extension of PRISMA for scoping reviews, was followed, and this study was conducted in 5 steps: 1 - formulation of the research question, according to the Population, Context, Concept - PCC method; 2 - selection of databases and definition of search terms and strategies; 3 - exporting studies to the Rayyan manager, establishing eligibility criteria; 4 - selection of articles by 2 blinded/independent reviewers; 5 - development of a spreadsheet with the evidence found, following the JBI Manual for Evidence Synthesis model. Results: This review included 15 articles that analyzed the efficacy of FMT in the treatment of IBS, using the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) as a parameter. 93.3% of the articles indicated some efficacy of the procedure, with the change in the recipient's gastrointestinal microbiome being the main hypothesis behind the therapeutic benefit. Discussion: Based on the results, FMT emerges as a therapeutic alternative in the treatment of IBS, but its efficacy depends on many variables that need to be further analyzed. Conclusion: The use of FMT in IBS has been beneficial, alleviating symptoms and improving patients' quality of life. However, the development of new studies is necessary to elucidate this topic.
Metrics
References
- Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, et al. Fecal microbiota transplantation: Review and update. Journal of the Formosan Medical Association. 2019 Mar 11; 118(1): S23–31. DOI: https://doi.org/10.1016/j.jfma.2018.08.011
- Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World Journal of Gastroenterology. 2014 Jun 14; 20(22): 6759–73. DOI: https://doi.org/10.3748/wjg.v20.i22.6759
- Jamshidi P, Yeganeh Farsi, Zahra Nariman, Mohammad Reza Hatamnejad, Benyamin Mohammadzadeh, Hossein Akbarialiabad, et al. Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Molecular Sciences. 2023 Sep 26; 24(19): 14562–2. DOI: https://doi.org/10.3390/ijms241914562
- Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann of Intern Med. 2018 Set 4; 169(7): 467-473. DOI: https://doi.org/10.7326/M18-0850
- Mattos SM, Cestari VRF, Moreira TMM. Scoping protocol review: PRISMA-ScR guide refinement. Rev Enferm UFPI. 2023 Mar 5; 12(1). DOI: https://doi.org/10.26694/reufpi.v12i1.3062
- Aromataris E, Munn Z [Editors]. JBI Manual for Evidence Synthesis. JBI, 2020.
- El‐Salhy M, Mazzawi T, Hausken T, Hatlebakk JG. Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation. Neurogastroenterology & Motility. 2022 Mar 18. 34(9): e14353. DOI: https://doi.org/10.1111/nmo.14353
- Mazzawi T, Hausken T, Hov JR, Valeur J, Sangnes DA, El-Salhy M, et al. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology. 2019 Jun 3; 54(6): 690–9. DOI: https://doi.org/10.1080/00365521.2019.1624815
- El-Salhy M, Casen C, Valeur J, Hausken T, Hatlebakk JG. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology. 2021 May 14; 27(18): 2219–37. DOI: https://doi.org/10.3748/wjg.v27.i18.2219
- Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. The Lancet Gastroenterology & Hepatology. 2018 Jan; 3(1): 17–24. DOI: https://doi.org/10.1016/S2468-1253(17)30338-2
- Cui J, Lin Z, Tian H, Yang B, Zhao D, Ye C, et al. Long-Term Follow-Up Results of Fecal Microbiota Transplantation for Irritable Bowel Syndrome: A Single-Center, Retrospective Study. Frontiers in Medicine. 2021 Jul 30; 8. DOI: https://doi.org/10.3389/fmed.2021.710452
- Yau YK, Su Q, Xu Z, Tang W, Ching JYL, Mak JWY, et al. Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea. Alimentory Pharmacology & Therapeutic. 2023 Sep 5; 58(8): 795-804. DOI: https://doi.org/10.1111/apt.17703
- Huang HL, Chen HT, Luo QL, Xu HM, He J, Li YQ, et al. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. Journal of Digestive Diseases. 2019 Aug 1; 20(8): 401–8. DOI: https://doi.org/10.1111/1751-2980.12756
- Madsen AMA, Halkjær SI, Christensen AH, Günther S, Browne PD, Kallemose T, et al. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study. Scandinavian Journal of Gastroenterology. 2021 May 17; 56(7): 761–9. DOI: https://doi.org/10.1080/00365521.2021.1915375
- Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018 Jul 6; 67(12): 2107–15. DOI: https://doi.org/10.1136/gutjnl-2018-316434
- Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. The Lancet Gastroenterology & Hepatology. 2019 Sep 1; 4(9): 675–85. DOI: https://doi.org/10.1016/S2468-1253(19)30198-0
- Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 2020 Jul 15. DOI: https://doi.org/10.1053/j.gastro.2020.07.013
- Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2020 Apr 28; 51(12): 1321–31. DOI: https://doi.org/10.1111/apt.15740
- Hamazaki M, Sawada T, Yamamura T, Maeda K, Mizutani Y, Ishikawa E, et al. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan. BMC Gastroenterology. 2022 Jul 14; 22(1). DOI: https://doi.org/10.1186/s12876-022-02408-5
- Mazzawi T, Lied GA, Sangnes DA, El-Salhy M, Hov JR, Gilja OH, et al. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. Green J, editor. PLOS ONE. 2018 Nov 14; 13(11): e0194904. DOI: https://doi.org/10.1371/journal.pone.0194904
- Fadieienko G D., Gridnyev O E., Dubrov K Y. Efficacy of fecal microbiota transplantation in patients with post-infection irritable bowel syndrome with diarrhea. Modern Gastroenterology. 2022 Jun 27; (1—2): 12–9. DOI: https://doi.org/10.30978/MG-2022-1-12
- Myneedu K, Deoker A, Schmulson MJ, Bashashati M. Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. United European Gastroenterol J. 2019 Oct 1; 7(8): 1033-41. DOI: https://doi.org/10.1177/2050640619866990
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rafael Vieira de Menezes, João Felipe de Paula Pessoa Lapenda, André Galvão Knopp, Maria Fernanda Diniz Ferreira , Felipe Lima Barros Ourem Campos, Maria Luiza Oliveira Costa, Guilherme Salcedo Crusco , Ana Luiza Melo Moura Ferreira, Hugo Rafael de Souza e Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
User licenses define how readers and the general public can use the article without needing other permissions. The Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders can use to share original works of authorship and other material subjects to copyright and certain other rights specified in the public license available at https:// creativecommons.org/licenses/by/4.0/deed.pt_BR. Using the 4.0 International Public License, Brazilian Medical Students (BMS) grants the public permission to use published material under specified terms and conditions agreed to by the journal. By exercising the licensed rights, authors accept and agree to abide by the terms and conditions of the Creative Commons Attribution 4.0 International Public License.
